Abiopharma

KAINOS GROUP PLC (AIMD)

Symbol	AIMD
Name	KAINOS GROUP PLC
Sector	HEALTH CARE
Region	Europe
Industry	-
Address	BT7 1NT United Kingdom 4-6 Upper Crescent
Telephone	+44 28 9057 1100
Fax	—
Email	—
Website	https://investor.kainos.com
Incorporation	GB
Incorporated On	—
Employees	—
Fiscal Year	12/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	—
Audit Status	NOT AVAILABLE
Reporting Status	International Reporting: LSE - London Stock Exchange
CIK	—
Description	Kainos (ancient Greek meaning new or fresh). Were one of the longest standing independent digital technology companies in the UK. We now have 13 offices across Europe and America. We provide a full lifecycle portfolio of bespoke digital technology solutions to public and private sector customers. We lead the market for the provision of Mobile-Enabled Healthcare solutions to the NHS. Additional info from NASDAQ: Ainos, Inc. (NASDAQ AIMD) is a dual platform AI and biotech company pioneering SmellTech, AI diagnostics, and immune therapeutics. Ainos proprietary AI Nose platform uses a breakthrough smell language model (SLM) to digitize scent into Smell IDs, turning invisible chemical signals into machine readable data. From robotics and smart factories to senior care and womens health, Ainos is giving AI the power to smell, unlocking a new frontier in sensory intelligence. With strategic partners, Ainos is scaling the first commercial digital olfaction platform. Ainos also develops VELDONA, a low dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. Multiple clinical programs are in motion Active clinical programs include HIV related oral warts, primary Sjogrens syndrome, and feline chronic gingivostomatitis (FCGS). Additional info from OTC: Kainos (ancient Greek meaning new or fresh). Were one of the longest standing independent digital technology companies in the UK. We now have 13 offices across Europe and America. We provide a full lifecycle portfolio of bespoke digital technology solutions to public and private sector customers. We lead the market for the provision of Mobile-Enabled Healthcare solutions to the NHS.

2026-04-17 20:15

Director tsai chun-hsien 🟡 adjusted position in 300.0K shares (2 derivative) of Ainos, Inc. (AIMD) at $1.61 Transaction Date: Apr 15, 2026 | Filing ID: 017846

2026-04-17 20:15

Director lee ting-chuan 🟡 adjusted position in 570.0K shares (2 derivative) of Ainos, Inc. (AIMD) at $1.61 Transaction Date: Apr 15, 2026 | Filing ID: 017844

2026-04-17 17:20

New Form SCHEDULE 13D/A - Ainos, Inc. Filed: 2026-04-17 AccNo: 0001493152-26-017868 Size: 8 KB

2026-04-17 17:20

New Form SCHEDULE 13D/A - Ainos, Inc. Filed: 2026-04-17 AccNo: 0001493152-26-017867 Size: 8 KB

2026-04-17 17:20

New Form SCHEDULE 13D/A - Ainos, Inc. Filed: 2026-04-17 AccNo: 0001493152-26-017865 Size: 11 KB

2026-04-15 10:21

ASE Test, Inc. 🟢 acquired 6.0K shares (1 derivative) of Ainos, Inc. (AIMD) at $22.50 Transaction Date: Apr 12, 2026 | Filing ID: 005723

2026-04-15 07:19

New Form SCHEDULE 13D/A - Ainos, Inc. Filed: 2026-04-15 AccNo: 0000950103-26-005722 Size: 92 KB

2026-03-30 21:30

(19% Negative) KAINOS GROUP PLC (AIMD) Reports Q1 2026 Financial Results

2026-02-13 18:29

New Form S-8 - Ainos, Inc. Filed: 2026-02-13 AccNo: 0001493152-26-006721 Size: 277 KB

2026-01-30 18:10

New Form SCHEDULE 13D/A - Ainos, Inc. Filed: 2026-01-30 AccNo: 0001493152-26-004492 Size: 10 KB

No clinical trials found for this company.

No clinical products found for this company.